IOP reductions of the magnitude seen from this report 13 were not reproduced in our series presumably due to the differences in pigmentation Brazilian eyes are more pigmented, absorb more laser energy and hence should illustrate a greater IOP drop side effects in our series were less common, which may again be explained by differences in laser energy uptake.
The pharmacological reformulation of shorter acting mydriasis drops to minimise side effects may reduce disruption to patients and potentially benefit uptake rates, although we acknowledge that this would not address the pain participants had reported.
Existing literature has highlighted supplementation with iron syrup/drops or tablet being prone to poor adherence because of several factors that include difficulty swallowing tablets [ 7], drops having gastrointestinal side effects like abdominal discomfort, unpleasant and strong metallic taste, staining of a child's teeth if not wiped off immediately and complicated dosing instructions [ 8, 9].
If we doctors fully understand the paradigm of EBM, and clearly explain that the eye drop sometimes has side effects and is not very effective, we'll succeed in persuading patients.
Reasons for drop out included: side effects (n = 4); new health issues (n = 2); no explanation provided (n = 4); left area (n = 1); switched to glatiramer acetate per patient preference (n = 1); sample hybridization not adequate at baseline or 6 month injection (n = 2).
In the four who dropped out, the side effects (edema in two, diarrhea in one, and heart palpitations in one) all resolved shortly after stopping celecoxib.
Of the four who dropped out, the side effects (edema in two, diarrhea in one, and heart palpitations in one) resolved shortly after stopping celecoxib.
Conversely, three women in the gabapentin arm dropped out after randomisation and before starting the drug, and three dropped out due to side effects (worsening vertigo and fatigue) and inefficacy.
The treatments took about a month to become effective, and while some patients reported headaches, none dropped out because of side effects.
Yet more than 20 percent of the patients in each of the trials dropped out because of side effects.
Indeed, Kenneth C. Frazier, Merck's president for global human health, seemed buoyant after the presentation on Monday because researchers had reported that 17 patients in the niacin arm of the study dropped out because of side effects.
